ERBB2 and breast carcinoma: Patients had received 0–3 prior lines of therapy for metastatic ER+/HER2-breast cancer, and 12-month PFS in this trial was 53% in patients who had received prior CDK4/6 inhibitor therapy (Wesolowski et al., 2022).